专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007096351A1 2, 4-DIAMINOPYRIMIDINDERIVATE ZUR BEHANDLUNG UND/ODER PRÄVENTION VON KREBS, INFEKTIONEN, ENTZÜNDUNGS- UND AUTOIMMUNERKRANKUNGEN 审中-公开
标题翻译： 2，用于治疗和/或预防癌症，感染，炎症和自身免疫性疾病的4-氨基嘧啶衍生物
公开(公告)号：WO2007096351A1
公开(公告)日：2007-08-30
申请号：PCT/EP2007/051599
申请日：2007-02-20
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , STADTMUELLER, Heinz , BAUM, Anke , BOEHMELT, Guido , ENGELHARDT, Harald , QUANT, Jens , SOLCA, Flavio , STEEGMAIER, Martin , ZAHN, Stephan Karl
发明人： STADTMUELLER, Heinz , BAUM, Anke , BOEHMELT, Guido , ENGELHARDT, Harald , QUANT, Jens , SOLCA, Flavio , STEEGMAIER, Martin , ZAHN, Stephan Karl
IPC分类号： C07D403/12 , C07D413/12 , C07D498/04 , A61K31/551 , A61K31/553 , A61P29/00 , A61P35/00 , A61P37/00
CPC分类号： C07D498/04 , C07D403/12 , C07D413/12 , C07D487/04
摘要： Die vorliegende Erfindung umfasst Verbindungen der allgemeinen Formel (1) worin R 1 bis R 6 , X und Y wie in Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, die durch exzessive oder anomale Zellproliferation charakterisiert sind, geeignet sind, sowie deren Verwendung zur Herstellung eines Arzneimittels mit den vorstehend genannten Eigenschaften.
摘要翻译：本发明包括通式（1）化合物，其中R ^{1 是如权利要求1中所定义至R ^{6 ，X和Y，这对于引起的疾病的治疗过度或异常细胞增殖为特征值，是合适的，以及它们对于具有上述特性的药物的制备中使用。}}

2. 发明申请

WO2006018182A1 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION 审中-公开
标题翻译：治疗涉及细胞增殖的疾病的组合
公开(公告)号：WO2006018182A1
公开(公告)日：2006-02-23
申请号：PCT/EP2005/008623
申请日：2005-08-09
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , MUNZERT, Gerd , STEEGMAIER, Martin , BAUM, Anke
发明人： MUNZERT, Gerd , STEEGMAIER, Martin , BAUM, Anke
IPC分类号： A61K31/4985 , A61K31/519 , A61K31/4409 , A61K31/435
CPC分类号： A61K31/4985 , A61K31/435 , A61K31/4409 , A61K31/519
摘要： The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
摘要翻译：本发明涉及用于治疗涉及细胞增殖的疾病的药物组合物。本发明还涉及用于治疗所述疾病的方法，其包括共同给药其中基团L，R 1，R 2，R 3，R 4和R 5具有权利要求和说明书中给出的含义的式（I）化合物1 任选地以其互变异构体，外消旋体，对映异构体，非对映异构体及其混合物的形式，并且任选地以其药理学上可接受的酸加成盐，溶剂化物，水合物，多晶型物，生理学功能衍生物或前药的形式和有效量的活性化合物2和/或与放射疗法共同治疗，提供增效和协同作用的比例，以及式（I）化合物1和有效量的活性化合物2和/或放射治疗用于制造相应的药物组合制剂。

3. 发明申请

WO2004018000A3 COMPOSITIONS AND METHODS FOR TREATING CANCER USING MAYTANSINOID CD44 ANTIBODY IMMONOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS 审中-公开
标题翻译：使用MAYTANSINOID CD44抗体免疫球蛋白和化疗药物治疗癌症的组合物和方法
公开(公告)号：WO2004018000A3
公开(公告)日：2004-09-02
申请号：PCT/EP0309166
申请日：2003-08-19
申请人： BOEHRINGER INGELHEIM INT , ADOLF GUENTHER , BAUM ANKE , HEIDER KARL-HEINZ
发明人： ADOLF GUENTHER , BAUM ANKE , HEIDER KARL-HEINZ
IPC分类号： A61K31/337 , A61K33/24 , A61K39/395 , A61K45/06 , A61K47/48 , A61P35/00
CPC分类号： A61K31/337 , A61K39/395 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2300/00
摘要： The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes.
摘要翻译：本发明涉及CD44特异性抗体与细胞毒性化合物和化学治疗剂的缀合物在癌症治疗中的组合使用，包含这些化合物和/或化学治疗剂的药物组合物和癌症治疗方法。优选的缀合物含有美登木素生物碱作为细胞毒性化合物，优选的化学治疗剂是紫杉烷类。

4. 发明申请

WO2006018182A8 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION 审中-公开
标题翻译：用于治疗涉及细胞增殖的疾病的组合
公开(公告)号：WO2006018182A8
公开(公告)日：2006-06-08
申请号：PCT/EP2005008623
申请日：2005-08-09
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , MUNZERT GERD , STEEGMAIER MARTIN , BAUM ANKE
发明人： MUNZERT GERD , STEEGMAIER MARTIN , BAUM ANKE
IPC分类号： A61K31/4985 , A61K31/435 , A61K31/4409 , A61K31/519
CPC分类号： A61K31/4985 , A61K31/435 , A61K31/4409 , A61K31/519
摘要： The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
摘要翻译：本发明涉及用于治疗涉及细胞增殖的疾病的药物组合物。本发明还涉及治疗所述疾病的方法，包括共同给予式（I）化合物1，其中基团L，R 1，R 2，R 3，R 4和R 5具有权利要求书和说明书中给出的含义，任选以其互变异构体，外消旋体，对映异构体，非对映体及其混合物的形式，并且任选呈药理学上可接受的酸加成盐，溶剂合物，水合物，多晶型物，生理功能衍生物或前药的形式，以及有效量的活性化合物2和/或以放射疗法共同治疗，以提供添加剂和协同效应的比例，以及组合使用式（I）化合物1和有效量的活性化合物2和/或放射治疗用于制造相应的药物组合制剂。

5. 发明申请

WO2006021544A1 2,4-DI(AMIMOPHEYL) PYRIMIDINE ALS PLK INHIBITOREN 审中-公开
标题翻译： 2,4-二（AMIMOPHEYL）嘧啶，其PLK抑制剂
公开(公告)号：WO2006021544A1
公开(公告)日：2006-03-02
申请号：PCT/EP2005/054089
申请日：2005-08-18
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , STADTMUELLER, Heinz , ENGELHARDT, Harald , STEEGMAIER, Martin , BAUM, Anke , GUERTLER, Ulrich , SCHOOP, Andreas , QUANT, Jens , SOLCA, Flavio , HAUPTMANN, Rudolf , REISER, Ulrich , ZAHN, Stephan Karl , HERFURTH, Lars
发明人： STADTMUELLER, Heinz , ENGELHARDT, Harald , STEEGMAIER, Martin , BAUM, Anke , GUERTLER, Ulrich , SCHOOP, Andreas , QUANT, Jens , SOLCA, Flavio , HAUPTMANN, Rudolf , REISER, Ulrich , ZAHN, Stephan Karl , HERFURTH, Lars
IPC分类号： C07D403/12 , C07D403/14 , C07D405/12 , C07D239/48 , C07D413/12 , A61K31/505 , A61K31/506 , A61K31/5513 , A61K31/553 , A61P29/00 , A61P35/00 , A61P37/00 , C07D401/12
CPC分类号： C07D239/42 , C07D239/48 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D413/12 , C07D413/14 , C07D453/02 , C07D471/04 , C07D487/04 , C07D487/08 , C07D491/08 , C07D491/10
摘要： Die vorliegende Erfindung umfasst Verbindungen der allgemeinen Formel (1), worin A, W, X, Y, Z, Ra, Rb, Rc, R1 und R3 wie in Anspruch 1 definiert sind, welche zur Behandlung von Krankheiten, die durch exzessive oder anomale Zellproliferation charakterisiert sind, geeignet sind, sowie deren Verwendung zur Herstellung eines Arzneimittels mit den vorstehend genannten Eigenschaften.
摘要翻译：本发明包括通式（1）化合物其中A，W，X，Y，Z，RA，RB，RC，如权利要求1中所定义，R 1和R 3，其用于治疗疾病的特征在于过度或异常细胞增殖的特征在于，是合适的，以及它们对于具有上述特性的药物的制备中使用。

6. 发明申请

WO2007054551A1 COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS 审中-公开
标题翻译：包含EGFR / HER2抑制剂的癌症的组合治疗
公开(公告)号：WO2007054551A1
公开(公告)日：2007-05-18
申请号：PCT/EP2006/068314
申请日：2006-11-09
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C., A. , BAUM, Anke
发明人： SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C., A. , BAUM, Anke
IPC分类号： A61K31/517 , A61K31/00 , A61P35/00
CPC分类号： C07D405/12 , A61K31/00 , A61K31/337 , A61K31/517 , A61K39/39558 , A61K45/06 , A61K2300/00
摘要： The invention relates to a therapy of cancer comprising co-administration to a person in need of such treatment and/or co-treatment of a person in need of such treatment with effective amounts of: (1) a compound 1 of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification; and (2) at least a further chemotherapeutic agent 2 ; optionally in combination with radiotherapy, radio-immunotherapy and/or tumour resection by surgery, furthermore, the invention relates to corresponding medicaments and the preparation thereof.
摘要翻译：本发明涉及癌症治疗，其包括共同给予需要这种治疗和/或共同治疗需要这种治疗的人的人，其有效量为：（1）式（I）化合物1，其中基团R a至R d具有权利要求书和说明书中给出的含义; 和（2）至少另外一种化学治疗剂2; 任选地与放射治疗，放射免疫治疗和/或手术的肿瘤切除术组合，此外，本发明涉及相应的药物及其制备。

7. 发明申请

WO2004096224A3 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS 审中-公开
公开(公告)号：WO2004096224A3
公开(公告)日：2004-11-11
申请号：PCT/EP2004/004363
申请日：2004-04-24
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , HILBERG, Frank , SOLCA, Flavio , STEFANIC, Martin Friedrich , BAUM, Anke , MUNZERT, Gerd , VAN MEEL, Jacobus, C.A.
发明人： HILBERG, Frank , SOLCA, Flavio , STEFANIC, Martin Friedrich , BAUM, Anke , MUNZERT, Gerd , VAN MEEL, Jacobus, C.A.
IPC分类号： A61K31/496
摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said deseases, coomprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

8. 发明申请

WO2004018000A2 COMPOSITIONS AND METHODS FOR TREATING CANCER USING CYTOTOXIC CD44 ANTIBODY IMMONOCONJUGATES AND CHEMOTHERAPEUTIC AGENTS 审中-公开
标题翻译：使用CYTOTOXIC CD44抗体免疫球蛋白和化学治疗剂治疗癌症的组合物和方法
公开(公告)号：WO2004018000A2
公开(公告)日：2004-03-04
申请号：PCT/EP2003/009166
申请日：2003-08-19
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , ADOLF, Günther , BAUM, Anke , HEIDER, Karl-Heinz
发明人： ADOLF, Günther , BAUM, Anke , HEIDER, Karl-Heinz
IPC分类号： A61K47/48
CPC分类号： A61K31/337 , A61K39/395 , A61K45/06 , A61K47/6803 , A61K47/6849 , A61K2300/00
摘要： The invention relates to the combined use of conjugates of CD44 specific antibodies with cytotoxic compounds and chemotherapeutic agents in cancer therapy, pharmaceutical compositions comprising such compounds and/or chemotherapeutic agents, and methods of cancer treatment. Preferred conjugates contain maytansinoids as cytotoxic compounds, and preferred chemotherapeutic agents are taxanes, epothilones, and vinca alcaloids.
摘要翻译：本发明涉及CD44特异性抗体与细胞毒性化合物和化学治疗剂的缀合物在癌症治疗中的组合使用，包含这些化合物和/或化学治疗剂的药物组合物和癌症治疗方法。优选的缀合物包含美登木素生物碱作为细胞毒性化合物，优选的化学治疗剂是紫杉烷类，埃坡霉素和长春花碱。

9. 发明申请

WO2007054550A1 QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES 审中-公开
标题翻译：喹诺酮衍生物治疗癌症
公开(公告)号：WO2007054550A1
公开(公告)日：2007-05-18
申请号：PCT/EP2006/068313
申请日：2006-11-09
申请人： BOEHRINGER INGELHEIM INTERNATIONAL GMBH , BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG , SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C.A. , BAUM, Anke
发明人： SOLCA, Flavio , AMELSBERG, Andree , STEHLE, Gerd , VAN MEEL, Jacobus C.A. , BAUM, Anke
IPC分类号： A61K31/517 , A61K31/553 , A61P35/00
CPC分类号： A61K31/517 , A61K31/553 , A61K33/24
摘要： The present invention relates to the use of quinazolines of formula (I), wherein the groups R a to R d have the meanings given in the claims and specification, in cancer therapy.
摘要翻译：本发明涉及式（I）的喹唑啉的用途，其中基团R a至R d具有权利要求和说明书中给出的含义，在癌症治疗中。

10. 发明申请

WO2004096224A2 COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION, MIGRATION OR APOPTOSIS OF MYELOMA CELLS, OR ANGIOGENESIS 审中-公开
标题翻译：治疗涉及细胞增殖，移植或吞噬MYELOMA细胞或血管生成的疾病的组合
公开(公告)号：WO2004096224A2
公开(公告)日：2004-11-11
申请号：PCT/EP2004004363
申请日：2004-04-24
申请人： BOEHRINGER INGELHEIM INT , BOEHRINGER INGELHEIM PHARMA , HILBERG FRANK , SOLCA FLAVIO , STEFANIC MARTIN FRIEDRICH , BAUM ANKE , MUNZERT GERD , VAN MEEL JACOBUS C A
发明人： HILBERG FRANK , SOLCA FLAVIO , STEFANIC MARTIN FRIEDRICH , BAUM ANKE , MUNZERT GERD , VAN MEEL JACOBUS C A
IPC分类号： A61K31/496 , A61K31/517 , A61K31/56 , A61K45/06 , A61P35/00
CPC分类号： A61K31/496 , A61K31/404 , A61K31/517 , A61K31/553 , A61K31/56 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a pharmaceutical combination for the treatment of diseases which involves cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis. The invention also relates to a method for the treatment of said deseases, coomprising co-administration of effective amounts of specific active compounds and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of these specific compounds and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.
摘要翻译：本发明涉及用于治疗涉及骨髓瘤细胞的细胞增殖，迁移或凋亡或血管发生的疾病的药物组合。本发明还涉及一种治疗所述疾病的方法，其以提供添加剂和协同效应的比例共同给予有效量的特定活性化合物和/或与放射治疗共同施用，以及组合使用这些特定化合物和/或放射治疗来制造相应的药物组合制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式